{"disease":{"id":"congenital-toxoplasmosis","name":"Congenital toxoplasmosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"spiramycin","indication_name":"Prophylaxis of congenital toxoplasmosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rovamycin","generic_name":"SPIRAMYCIN","company_name":"Sanofi KK","drug_phase":"marketed","molecular_target":"","drug_class":"spiramycin","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"sulfadiazine","indication_name":"Congenital toxoplasmosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01202500","title":"Assessment of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":302,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT05774496","title":"Pregnancy and Congenital Toxoplasmosis","phase":"","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04825600","title":"Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity (TOXCELL)","phase":"NA","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}